Skip to Content

Investor Relations

Investor Relations

Company Overview

Arsanis is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases. Monoclonal antibodies, or mAbs, are a well-established therapeutic class across many disease areas; however, they have yet to be broadly utilized for the prevention or treatment of acute bacterial and viral infections, where they hold the potential to address serious unmet medical needs. Unlike antibiotics that propagate resistance, disrupt both disease-causing and beneficial bacteria and have adverse off-target effects, mAbs have the ability to precisely bind only to an intended target, thereby avoiding these undesired consequences. Our expertise lies in applying our deep understanding of infectious disease pathogenesis paired with our ability to access some of the most advanced mAb discovery techniques and platforms available today. We have used this expertise to discover and develop novel mAbs with multiple mechanisms of action and high potency against their intended targets.

Our lead product candidate, ASN100, is a first-in-class mAb therapeutic in Phase 2 clinical development for the prevention of Staphylococcus aureus, or S. aureus, pneumonia in high-risk, mechanically ventilated patients, a potentially life-threatening and costly infection for which there are no approved preventive therapies. ASN100 is a fully human mAb product candidate that we developed specifically to neutralize the six cytotoxins critical to S. aureus pneumonia pathogenesis, a scientific advancement that has not previously been achieved. Given its unique mechanism of action, we believe that ASN100 could improve the standard of care for mechanically ventilated patients who are heavily colonized with S. aureus and are therefore at high risk of developing life-threatening pneumonia. In addition to ASN100, our preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus, or RSV.

News Releases

June 14, 2018 at 8:00 AM EDT

Second recent transaction with Bravos Biosciences consolidates development of Arsanis gram-negative mAb candidates with global experts in anti-infective drug development WALTHAM, Mass. and VIENNA, Austria , June 14, 2018 (GLOBE NEWSWIRE) -- Arsanis, Inc.

May 10, 2018 at 7:00 AM EDT

ASN100 Phase 2 Trial Interim Analysis Results Expected in Late June WALTHAM, Mass. & VIENNA --(BUSINESS WIRE)--May 10, 2018-- Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious

April 17, 2018 at 8:00 AM EDT

WALTHAM, Mass. & VIENNA --(BUSINESS WIRE)--Apr. 17, 2018-- Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases, announced today that the company will present five scientific

Stock Information

Copyright Nasdaq. Minimum 15 minutes delayed.

Top